University of Texas/Texas AM Investment Management Co (UTIMCO)’s Denali Therapeutics DNLI Stock Holding History

University of Texas/Texas AM Investment Management Co (UTIMCO)’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,428	Closed	-$653K	–	167
2023 Q4	$653K	Buy	+30,428	New	+$603K	0.18%	49
2023 Q3	–	Sell	-36,513	Closed	-$1.08M	–	99
2023 Q2	$1.08M	Buy	+36,513	New	+$1.03M	0.42%	8
2021 Q4	–	Sell	-41,918	Closed	-$2.12M	–	48
2021 Q3	$2.12M	Buy	+41,918	New	+$2.36M	1.21%	9
2021 Q2	–	Sell	-23,629	Closed	-$1.35M	–	20
2021 Q1	$1.35M	Buy	+23,629	New	+$1.58M	0.79%	10

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO)'s DNLI Position: Q1 2024 in Review

University of Texas/Texas AM Investment Management Co (UTIMCO) sold out of Denali Therapeutics (DNLI) in Q1 2024, closing a stake of 30,428 shares — an estimated $653K sold.

University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in DNLI in Q1 2021 and held it in 4 quarters. The position peaked at $2.12M in Q3 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

University of Texas/Texas AM Investment Management Co (UTIMCO) reported no remaining Denali Therapeutics position as of Q1 2024 after selling out during the quarter.
University of Texas/Texas AM Investment Management Co (UTIMCO) sold 30,428 Denali Therapeutics shares in Q1 2024, an estimated $653K.
University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in Denali Therapeutics in Q1 2021 and held it in 4 quarters.
University of Texas/Texas AM Investment Management Co (UTIMCO)'s Denali Therapeutics position peaked at $2.12M in Q3 2021.
210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q1 2024, filed 30 Apr 2024.